Glioma

Score 7.4 = 7.4 leading Phase 2+ trials + 0.1 other trial roles + 0 talks + 0 posters. 4 of 5 trials are Phase 2+.

• Ph3NCT07291102 · Nationwide Children's Hospital · Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma
• Ph2NCT06161974 · Rigel Pharmaceuticals · Study of Olutasidenib and Temozolomide in HGG
• Ph2NCT05096481 · Nationwide Children's Hospital · PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
• Ph2NCT05843253 · Nationwide Children's Hospital · Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
• Ph1NCT03605550 · Nationwide Children's Hospital · A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma

Score 5 = 4.9 leading Phase 2+ trials + 0.1 other trial roles + 0 talks + 0 posters. 2 of 3 trials are Phase 2+.

• Ph2NCT07649070 · M.D. Anderson Cancer Center · Phase 2 Trial of G207 + 5 Gy Radiation for Children With High-Grade Gliomas
• Ph1NCT03911388 · M.D. Anderson Cancer Center · HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
• Ph2NCT04482933 · Pediatric Brain Tumor Consortium · HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma

Score 4.3 = 4.3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph1/Ph2NCT06639607 · Washington University School of Medicine · PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma
• Ph2NCT05096481 · Nationwide Children's Hospital · PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

Score 4 = 3 leading Phase 2+ trials + 1 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph3NCT07291102 · Nationwide Children's Hospital · Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma
• Ph2NCT07521657 · University of Alabama at Birmingham · Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma

Score 4 = 2.6 leading Phase 2+ trials + 1.3 other trial roles + 0 talks + 0 posters. 2 of 6 trials are Phase 2+.

• Ph2NCT07110246 · University of California, San Francisco · Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas
• Ph1NCT07492316 · University of Florida · RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB)
• Ph1NCT04485559 · University of California, San Francisco · Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
• Ph1NCT05478837 · University of California, San Francisco · Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Mutated Glioma
• Ph2NCT05009992 · University of California, San Francisco · Combination Therapy for the Treatment of Diffuse Midline Gliomas
• Ph1NCT03749187 · University of California, San Francisco · BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

Score 3.9 = 1.7 leading Phase 2+ trials + 2.2 other trial roles + 0 talks + 0 posters. 1 of 4 trials are Phase 2+.

• Ph1/Ph2NCT05660408 · University of Florida · RNA Lipid Particles Targeting Pediatric Recurrent Intracranial Malignancies and Other systEmic Solid Tumors
• Ph1NCT06514898 · University of Florida · Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma
• Ph1NCT06946680 · University of Florida · IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Newly Diagnosed and Recurrent Pediatric High-grade Glioma (pHGG) and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (ndDIPG)
• Ph1NCT07031765 · University of Florida · Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade Glioma

Score 3.9 = 3 leading Phase 2+ trials + 0.9 other trial roles + 0 talks + 0 posters. 1 of 2 trials are Phase 2+.

• Ph3NCT06448286 · Jonsson Comprehensive Cancer Center · PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glioblastoma
• Ph1NCT07218367 · VA Office of Research and Development · Phase I Trial of pH Resections of GBM at VA

Score 3.7 = 3.7 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph2NCT07916389 · St. Jude Children's Research Hospital · Molecularly Stratified Trial for Newly Diagnosed Infant-Type Hemispheric Glioma
• Ph2NCT05535166 · St. Jude Children's Research Hospital · Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

Score 3.5 = 3.2 leading Phase 2+ trials + 0.3 other trial roles + 0 talks + 0 posters. 2 of 3 trials are Phase 2+.

• Ph1/Ph2NCT07859059 · University of Nebraska · Metronomic Temozolomide With Dexbrompheniramine for Recurrent High-Grade Glioma/Glioblastoma
• Ph1NCT05698524 · University of Nebraska · A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
• Ph2NCT03728673 · University of Nebraska · A Study Utilizing Escitalopram in Glioma Patients

Score 3.4 = 3.4 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph3NCT06809322 · European Organisation for Research and Treatment of Cancer - EORTC · Vorasidenib Maintenance for IDH Mutant Astrocytoma
• Ph3NCT05904119 · European Organisation for Research and Treatment of Cancer - EORTC · Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study

Score 3.3 = 3.2 leading Phase 2+ trials + 0.1 other trial roles + 0 talks + 0 posters. 2 of 5 trials are Phase 2+.

• Ph1NCT03535350 · Case Comprehensive Cancer Center · Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma
• Ph2NCT05607407 · Case Comprehensive Cancer Center · Methimazole in Patients With Progressive Glioblastoma
• Ph2NCT07003542 · Case Comprehensive Cancer Center · A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas
• Ph1NCT03514069 · Case Comprehensive Cancer Center · Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma
• Ph1NCT02669173 · Case Comprehensive Cancer Center · Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma

Score 3.1 = 2.6 leading Phase 2+ trials + 0.5 other trial roles + 0 talks + 0 posters. 1 of 3 trials are Phase 2+.

• Ph1NCT04015700 · Washington University School of Medicine · Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma
• Ph1/Ph2NCT07392957 · Washington University School of Medicine · Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma
• Ph1NCT05743595 · Washington University School of Medicine · Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma

Score 3 = 1.7 leading Phase 2+ trials + 1.3 other trial roles + 0 talks + 0 posters. 2 of 5 trials are Phase 2+.

• Ph1NCT06254326 · University of Florida · ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients
• Ph1NCT06389591 · University of Florida · RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM)
• Ph1NCT05353530 · University of Florida · IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma
• Ph2NCT06558214 · University of Florida · OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial
• Ph2NCT03405792 · University of Florida · Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)

Score 3 = 2.8 leading Phase 2+ trials + 0.2 other trial roles + 0 talks + 0 posters. 1 of 2 trials are Phase 2+.

• Ph1NCT05556473 · Barbara Ann Karmanos Cancer Institute · F-Tryptophan PET/CT in Human Cancers
• Ph2NCT07735819 · Barbara Ann Karmanos Cancer Institute · Positron Emission Tomography/Computed Tomography (PET/CT) Imaging in Patients Diagnosed With a Glioma

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph3NCT07912398 · Hutchmed · HMPL-306 in Participants With Postoperative Residual or Recurrent Grade 2 Glioma Harboring IDH1 or IDH2 Mutations

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07891286 · National Cancer Institute (NCI) · Mirdametinib to Reduce the Size of Large/Giant Congenital Melanocytic Nevi in Children, Adolescents and Young Adults

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07832123 · University of Zurich · Safusidenib for Patients With Newly Diagnosed IDH1-mutant CNS WHO Grade 3 Oligodendroglioma and Astrocytoma - a Single Arm Phase II Study

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07620548 · Washington University School of Medicine · Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent Glioblastomas

Score 3 = 2.7 leading Phase 2+ trials + 0.3 other trial roles + 0 talks + 0 posters. 1 of 2 trials are Phase 2+.

• Ph1/Ph2NCT07416188 · National Institute of Neurological Disorders and Stroke (NINDS) · Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
• Ph1NCT05413304 · National Cancer Institute (NCI) · Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT07389278 · Sabine Mueller, MD, PhD · Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)

Score 2.9 = 2.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07694089 · Akshitkumar MIstry · Steroid Avoidance, Dexamethasone, and RAGE Inhibition for Perioperative Cerebral Edema Management in High-Grade Gliomas

Score 2.9 = 2.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07821112 · University of California, Irvine · Phase II Elderly/Frail Pts With Newly Diagnosed or Recurrent Malignant Glioma Treated With Cesium-131 GammaTile®

Score 2.9 = 2.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT07831187 · First Affiliated Hospital of Wenzhou Medical University · Entacapone Plus Bevacizumab for Glioblastoma at First Recurrence

Score 2.9 = 2.8 leading Phase 2+ trials + 0.1 other trial roles + 0 talks + 0 posters. 1 of 2 trials are Phase 2+.

• Ph2NCT07708961 · Mayo Clinic · Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma
• Ph1NCT04197934 · Mayo Clinic · WSD0922-FU for Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases

Score 2.9 = 2.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2/Ph3NCT07873996 · Beijing Tiantan Hospital · Tris-CAR-T Cell Therapy Targeting CD44 and CD133 in Newly Diagnosed Glioblastoma

Score 2.9 = 2.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2/Ph3NCT07873996 · Beijing Tiantan Hospital · Tris-CAR-T Cell Therapy Targeting CD44 and CD133 in Newly Diagnosed Glioblastoma

Score 2.9 = 2.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07856069 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Arsenic Trioxide Combined With Chemotherapy for Relapsed SHH-Activated and/or TP53-Mutant Medulloblastoma

Score 2.8 = 2.8 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07831369 · Inova Health Care Services · VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent Glioma

Score 2.8 = 2.8 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT07811297 · Advenchen Pharmaceuticals, LLC. · A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers

Score 2.8 = 2.8 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07356973 · CRISM Therapeutics LTD · Irinotecan-ChemoSeed in Surgically Resectable Glioblastoma

Score 2.7 = 2.6 leading Phase 2+ trials + 0.1 other trial roles + 0 talks + 0 posters. 3 of 4 trials are Phase 2+.

• Ph1/Ph2NCT05588141 · National Cancer Institute (NCI) · 000860: A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
• Ph1/Ph2NCT06161519 · National Cancer Institute (NCI) · PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
• Ph1NCT04216329 · National Cancer Institute (NCI) · Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
• Ph2NCT04817254 · National Cancer Institute (NCI) · Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Score 2.7 = 2.7 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT06492486 · Tata Memorial Centre · Glioma Adaptive Radiotherapy With Development of an Artificial Intelligence Workflow

Score 2.7 = 2.7 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07301268 · Mayo Clinic · GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma

Score 2.7 = 2.7 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph3NCT07452458 · NRG Oncology · Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma

Score 2.6 = 2.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 2 trials are Phase 2+.

• Ph3NCT07215910 · Alliance for Clinical Trials in Oncology · Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
• Ph1NCT00268385 · National Cancer Institute (NCI) · Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas

Score 2.6 = 2.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph3NCT07215910 · Alliance for Clinical Trials in Oncology · Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

Score 2.6 = 2.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT07468136 · Mayo Clinic · Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas

Score 2.6 = 2.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph3NCT07215910 · Alliance for Clinical Trials in Oncology · Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

Score 2.5 = 2.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT06528691 · St. Jude Children's Research Hospital · Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

Score 2.5 = 2.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT06465199 · Milton S. Hershey Medical Center · Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas